Dose Response Effect of High‐Dose Fluconazole for HIV‐Associated Cryptococcal Meningitis in Southwestern Uganda | Zendy

Nicky Longley | Zendy; Conrad Muzoora | Zendy; Kabanda Taseera | Zendy; James Mwesigye | Zendy; Joselyne Rwebembera | Zendy; Ali Chakera | Zendy; Emma Wall | Zendy; Irene Andia | Zendy; Shabbar Jaffar | Zendy; Thomas S. Harrison | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dose Response Effect of High‐Dose Fluconazole for HIV‐Associated Cryptococcal Meningitis in Southwestern Uganda

Author(s) -

Nicky Longley,

Conrad Muzoora,

Kabanda Taseera,

James Mwesigye,

Joselyne Rwebembera,

Ali Chakera,

Emma Wall,

Irene Andia,

Shabbar Jaffar,

Thomas S. Harrison

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/593194

Subject(s) - fluconazole , medicine , dose , meningitis , pharmacodynamics , pharmacokinetics , cryptococcal meningitis , gastroenterology , toxicity , surgery , human immunodeficiency virus (hiv) , immunology , viral disease , antifungal , dermatology

Therapy for human immunodeficiency virus (HIV)-associated cryptococcal meningitis in many centers in Africa is fluconazole administered at a dosage of 400-800 mg per day. However, higher dosages of fluconazole have been used to treat patients without resulting in serious toxicity. Pharmacokinetic and pharmacodynamic considerations suggest that higher dosages might be associated with greater efficacy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research